Please login to the form below

Not currently logged in
Email:
Password:

Sarepta

This page shows the latest Sarepta news and features for those working in and with pharma, biotech and healthcare.

Sarepta to assess imlifidase as pre-treatment to Duchenne muscular dystrophy gene therapy

Sarepta to assess imlifidase as pre-treatment to Duchenne muscular dystrophy gene therapy

LGMD). Søren Tulstrup, president and chief executive officer of Hansa, said: "We are very excited about the results we have seen in the preclinical phase of our collaboration with Sarepta. ... Sarepta submitted a Biologics License Application to the US

Latest news

More from news
Approximately 21 fully matching, plus 27 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...
Pharmaceutical Marketing Strategies For The Digital Age
In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...